Viking Therapeutics, Inc. (VKTX)
37.98
-0.57
(-1.48%)
USD |
NASDAQ |
Dec 08, 16:00
37.91
-0.07
(-0.18%)
Pre-Market: 08:54
Viking Therapeutics Research and Development Expense (Quarterly): 89.95M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.466B |
| Pfizer Inc. | 2.492B |
| Amgen, Inc. | 1.90B |
| Altimmune, Inc. | 14.93M |
| Terns Pharmaceuticals, Inc. | 19.92M |